ArticleEmerging infectious diseases2022
Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07287137 (IDCRP-154), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of natural killer cell depletion on innate and adaptive immune responses to COVID mRNA vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity.Npj viruses · 2025Article
- Article
- Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis.Drugs in R&D · 2025Article
- Article
- Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses.Vaccines · 2024Review
- Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques.iScience · 2024Article
- The Seraph 100Antibodies (Basel, Switzerland) · 2024Article
- Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.Nature communications · 2024Article
- SARS-CoV-2 Seroprevalence and Vaccine Uptake among Pregnant Women at First Antenatal Care Visits in Malawi.The American journal of tropical medicine and hygiene · 2024Article
- Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- Antibody Response to SARS-CoV-2 Vaccination in Heart Failure Patients: Retrospective Single-Center Cohort Study.Diagnostics (Basel, Switzerland) · 2023Article
- Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination.Nature communications · 2023Article
- Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.Cell reports · 2023Article
- Dynamics of Anti-S IgG Antibodies Titers after the Second Dose of COVID-19 Vaccines in the Manual and Craft Worker Population of Qatar.Vaccines · 2023Article
- Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability.Frontiers in immunology · 2023Observational
- SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.Frontiers in immunology · 2023Observational
- Article
- Effectiveness of Booster and Influenza Vaccines against COVID-19 among Healthcare Workers, Taiwan.Emerging infectious diseases · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 5 institutions in 1 country.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies decay but persist 6 months postvaccination; lower levels of neutralizing titers persist against Delta than wild-type virus. Of 227 vaccinated healthcare workers tested, only 2 experienced outpatient symptomatic breakthrough infections, despite 59/227 exhibiting serologic evidence of SARS-CoV-2 infection, defined as presence of nucleocapsid protein antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.